{
  "ticker": "RGNX",
  "company_name": "REGENXBIO Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT07236606",
      "title": "RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "MPS II, Hunter Syndrome (MPS II)",
      "start_date": "2025-11-25",
      "completion_date": "2031-05-30",
      "enrollment": 0,
      "sponsor": "REGENXBIO Inc."
    },
    {
      "nct_id": "NCT05407636",
      "title": "Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD",
      "status": "RECRUITING",
      "phase": "PHASE3",
      "condition": "AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV",
      "start_date": "2022-01-13",
      "completion_date": "2027-11",
      "enrollment": 0,
      "sponsor": "AbbVie"
    },
    {
      "nct_id": "NCT04462692",
      "title": "An Observational Study in Children With CLN2 Batten Disease",
      "status": "WITHDRAWN",
      "phase": "",
      "condition": "Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)",
      "start_date": "2021-03-31",
      "completion_date": "2023-10",
      "enrollment": 0,
      "sponsor": "REGENXBIO Inc."
    },
    {
      "nct_id": "NCT04704921",
      "title": "Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD",
      "status": "RECRUITING",
      "phase": "PHASE2, PHASE3",
      "condition": "AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization",
      "start_date": "2020-12-29",
      "completion_date": "2027-11",
      "enrollment": 0,
      "sponsor": "AbbVie"
    },
    {
      "nct_id": "NCT03529786",
      "title": "Mucopolysaccharidosis Type II Natural History",
      "status": "COMPLETED",
      "phase": "",
      "condition": "Mucopolysaccharidosis II",
      "start_date": "2017-09-27",
      "completion_date": "2022-03-22",
      "enrollment": 0,
      "sponsor": "REGENXBIO Inc."
    },
    {
      "nct_id": "NCT05693142",
      "title": "AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)",
      "status": "RECRUITING",
      "phase": "PHASE2, PHASE3",
      "condition": "Duchenne Muscular Dystrophy",
      "start_date": "2023-01-04",
      "completion_date": "2028-08",
      "enrollment": 0,
      "sponsor": "REGENXBIO Inc."
    },
    {
      "nct_id": "NCT04514653",
      "title": "RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Neovascular Age-Related Macular Degeneration (nAMD)",
      "start_date": "2020-08-25",
      "completion_date": "2027-02",
      "enrollment": 0,
      "sponsor": "AbbVie"
    },
    {
      "nct_id": "NCT03566043",
      "title": "CAMPSIITE\u2122 RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome)",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE2, PHASE3",
      "condition": "Mucopolysaccharidosis Type II (MPS II)",
      "start_date": "2018-09-27",
      "completion_date": "2025-08",
      "enrollment": 0,
      "sponsor": "REGENXBIO Inc."
    },
    {
      "nct_id": "NCT03066258",
      "title": "Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration",
      "start_date": "2017-03-29",
      "completion_date": "2021-06-17",
      "enrollment": 0,
      "sponsor": "REGENXBIO Inc."
    },
    {
      "nct_id": "NCT05683379",
      "title": "AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD",
      "status": "RECRUITING",
      "phase": "",
      "condition": "Duchenne Muscular Dystrophy",
      "start_date": "2022-12-20",
      "completion_date": "2026-09",
      "enrollment": 0,
      "sponsor": "REGENXBIO Inc."
    }
  ],
  "summary": {
    "total_trials": 22,
    "by_phase": {
      "PHASE3": 2,
      "": 10,
      "PHASE2, PHASE3": 3,
      "PHASE2": 3,
      "PHASE1, PHASE2": 4
    },
    "by_status": {
      "RECRUITING": 7,
      "WITHDRAWN": 3,
      "COMPLETED": 4,
      "ACTIVE_NOT_RECRUITING": 2,
      "UNKNOWN": 3,
      "ENROLLING_BY_INVITATION": 2,
      "TERMINATED": 1
    },
    "active_trials": 11,
    "completed_trials": 4,
    "conditions": [
      "AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization",
      "AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV",
      "Diabetic Macular Edema",
      "Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)",
      "Duchenne Muscular Dystrophy",
      "Homozygous Familial Hypercholesterolemia (HoFH)",
      "Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)",
      "MPS II, Hunter Syndrome (MPS II)",
      "Mucopolysaccharidosis I",
      "Mucopolysaccharidosis II",
      "Mucopolysaccharidosis Type I (MPS I), Hurler Syndrome, Hurler-Scheie Syndrome",
      "Mucopolysaccharidosis Type II (MPS II)",
      "Neovascular Age-Related Macular Degeneration (nAMD)",
      "Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration",
      "Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:44:50.212836",
    "search_query": "REGENXBIO Inc.",
    "url": "https://clinicaltrials.gov/search?term=REGENXBIO+Inc."
  }
}